Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress

Antioxidants and Redox Signaling

Volumn 7, Issue 11-12, 2005, Pages 1521-1529

  Kellogg, Aaron P ^a   Pop Busui, Rodica ^a,b,c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; KNOCKOUT MOUSE; MALE; MOTOR NERVE CONDUCTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION;

ALKENES; ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ENZYME ACTIVATION; GLUTATHIONE; HYDROXYLATION; LIPID PEROXIDATION; MALONDIALDEHYDE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PERIPHERAL NERVES; PROSTAGLANDINS; STREPTOZOCIN;

ANIMALIA;

EID: 28844487899     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1521     Document Type: Article

References (51)

1. [No authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comments]. N Engl J Med 329: 977-986, 1993.
2. [No authors listed] Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38: 869-880, 1995.
3. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 352: 837-853, 1998.
4. Adderley SR and Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274: 5038-5046, 1999.
5. Brock TG, McNish RW, and Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 274: 11660-11666, 1999.
6. Cameron NE and Cotter MA. Comparison of the effects of chronic aldose reductase inhibitor and acetyl-L-cysteine treatment on peripheral nerve blood flow and function in anesthetized diabetic rats. J Physiol (Lond) 483P: 142P, 1995.
7. Cameron NE and Cotter MA. Comparison of the effects of ascorbyl-gamma-linolenic acid and gamma-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetologia 39: 1047-1054, 1996.
8. Cameron NE and Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46(Suppl 2): 31S-37S, 1997.
9. Cameron NE, Cotter MA, Dines KC, Robertson S, and Cox D. The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rats: modulation by the cyclo-oxygenase inhibitor flurbiprofen. Br J Pharmacol 109: 972-979, 1993.
10. Cameron NE, Cotter MA, and Maxfield EK. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 36: 299-304, 1993.
11. Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, and Mirrlees DJ. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37: 651-663, 1994.
12. Cameron NE, Cotter MA. and Hohman TC. Interactions between essential fatty acid, prostenoid, polyol pathway and nitric oxide metabolism in the neurovascular deficit of diabetic rats. Diabetologia 39: 172-182, 1996.
13. Cameron NE, Cotter MA, Jack A, and Hohman TC. Inhibition of protein kinase C corrects nerve conduction and blood flow deficits in diabetic rats. Diabetologia 40: A115, 1997.
14. Cameron NE, Cotter MA, Horrobin DH, and Tritschler HJ. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 41: 390-399, 1998.
15. +-ATPase activity and glutathione content in diabetic rats. Diabetologia 42: 1120-1130, 1999.
16. Cosentino F, Barker JE, Brand MP, Heales SJ, Werner ER, Tippins JR, West N, Channon KM, Volpe M, and Luscher TF. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol 2l: 496-502, 2001.
17. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, and Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107: 1017-1023, 2003.
18. Cotter MA and Cameron NE. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 56: 337-343, 1997.
19. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, and Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974, 2000.
20. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
21. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE. Cyclooxygenase in biology and disease [see comments]. FASEB J. 12: 1063-1073, 1998.
22. Faux SP and Howden PJ. Possible role of lipid peroxidation in the induction of NF-kappa B and AP-1 in RFL-6 cells by crocidolite asbestos: evidence following protection by vitamin E. Environ Health Perspect 105 Suppl 5: 1127-1130, 1997.
23. Feng L, Xia Y, Garcia GE, Hwang D, and Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 95: 1669-1675, 1995.
24. Greene DA, Stevens MJ, Obrosova I, and Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 375: 217-223, 1999.
25. Gross G, Imamura T, Vogt SK, Wozniak DF, Nelson DM, Sadovsky Y, and Muglia LJ. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. Am J Physiol Regul Integr Comp Physiol 278: R1415-R1423, 2000.
26. Harrison HE, Reece AH, and Johnson M. Decreased vascular prostacyclin in experimental diabetes. Life Sci 23: 354-356, 1978.
27. Herschman HR, Reddy ST, and Xie W. Function and regulation of prostaglandin synthase-2. Adv Exp Med Biol 407: 61-66, 1997.
28. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, and Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 88: 6107-6111, 1991.
29. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, and Araki E. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52: 2570-2577, 2003.
30. Langenbach R, Loftin CD, Lee C, and Tiano H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann NY Acad Sci 889: 52-61, 1999.
31. Low PA, Nickander KK, and Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46(Suppl 2): 38S-42S, 1997.
32. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
33. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
34. Obrosova I, Fathallah L, Stockert C, Kennedy A, Frank R, and Stevens M. Early upregulation of vascular endothelial growth factor (VEGF) in the diabetic rat retina: attenuation by taurine. Diabetes A172, 2000.
35. Obrosova IG, Fathallah L, and Greene DA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol 398: 139-146, 2000.
36. Parry GJ and Kozu H. Piroxicam may reduce the rate of progression of experimental diabetic neuropathy. Neurology 40: 1446-1449, 1990.
37. Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, and Stevens MJ. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. Exp Neurol 168: 259-272, 2001.
38. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, and Stevens MJ. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51: 2619-2628, 2002.
39. Shimizu K, Muramatsu M, Kakegawa Y, Asano H, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, and Ito T. Role of prostaglandin H2 as an endothelium-derived contracting factor in diabetic state. Diabetes 42: 1246-1252, 1993.
40. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291-295, 1997.
41. Sima AAF, Ristic H, Merry A, Kamijo M, Lattimer SA, Stevens MJ, and Greene DA. The primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the BB/W-rat. J Clin Invest 97: 1900-1907, 1996.
42. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94: 853-859, 1994.
43. Stevens MJ, Obrosova I, Cao X, Van Huysen C, and Greene DA. Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49: 1006-1015, 2000.
44. Subbiah MTR and Deitemeyer D. Altered synthesis of prostaglandins in platelet and aorta from spontaneously diabetic Wistar rats. Biochem Med 23: 231-235, 1980.
45. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 16: 383-391, 1994.
46. Tesfamariam B, Brown ML, Deykin D, and Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 85: 929-932, 1990.
47. Tesfamariam B, Brown ML, and Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87: 1643-1648, 1991.
48. Williams CS and DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270: G393-G400, 1996.
49. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 33: 179-207, 1995.
50. Yasuda H, Sonobe M, Yamashita M, Terada M, Hatanaka I, Huitian Z, and Shigeta Y. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes 38: 832-838, 1989.
51. Zochodne DW and Ho LT. The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy. Can J Neurol Sci 21:194-202, 1994.